<DOC>
	<DOCNO>NCT01741532</DOCNO>
	<brief_summary>A multi-center , placebo control , double-blind trial compare efficacy safety 18 month treatment deferiprone versus placebo patient PKAN . This investigator-initiated trial fund European Commission 's Seventh Framework Programme ( FP7/2007-2013 , HEALTH-F2-2011 , grant agreement No . 277984 ) TIRCON consortium ( Treat Iron-Related Childhood-Onset Neurodegeneration ) FDA OOPD ( Dr. Elliott Vichinsky )</brief_summary>
	<brief_title>A Two-arm Efficacy Safety Study Deferiprone Patients With Pantothenate Kinase-associated Neurodegeneration ( PKAN )</brief_title>
	<detailed_description />
	<mesh_term>Nerve Degeneration</mesh_term>
	<mesh_term>Pantothenate Kinase-Associated Neurodegeneration</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Deferiprone</mesh_term>
	<criteria>Main Males females 4 year age old screen visit ; Have PKAN , confirm genetic testing ( support evidence require ) ; BAD total score â‰¥ 3 screen visit ; Patients Deep Brain Stimulation ( DBS ) system baclofen pumps place eligible study , must stable set least two month prior screen visit stimulation parameter / pump setting must remain stable duration trial : Main Evidence iron deficiency define Fe : TIBC ratio &lt; 15 % , serum ferritin &lt; 12 ng/mL ; Treatment deferiprone past 12 month ; Previous failure treatment deferiprone , previous discontinuation treatment deferiprone due adverse event ; Conditions know contraindicate use deferiprone ( history agranulocytosis recurrent episode neutropenia ) ; A serious , unstable chronic illness relate PKAN condition past 3 month screen visit include limited : hepatic , renal , gastroenterologic , respiratory , cardiovascular , endocrinologic , neurologic immunologic disease ; Evidence abnormal liver renal function ( serum liver enzyme level ( ) &gt; 3 time upper limit normal screening ) abnormal creatinine level screen visit ; Disorders associate neutropenia ( ANC &lt; 1.5 x 10E9/L ) thrombocytopenia ( platelet count &lt; 50 x 10E9/L ) 12 month precede initiation study medication . Exception : patient whose neutropenia attribute treat physician episode infection drug associate decline neutrophil count ANC fully recover screening visit ; History malignancy ; Other protocol inclusion exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pantothenate Kinase-associated Neurodegeneration</keyword>
	<keyword>PKAN</keyword>
	<keyword>NBIA</keyword>
	<keyword>Deferiprone</keyword>
	<keyword>Ferriprox</keyword>
</DOC>